MediWound Reports Fourth Quarter and Fiscal Year 2017 Financial Results

MediWound (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today...

Aeolus Announces Presentation of Pharmacometric Analysis

Aeolus Pharmaceuticals announced the presentation of new data on AEOL 10150 for the treatment of the pulmonary effects of acute...

Cytori Gets Green Light for Thermal Burn Clinical Trial

Cytori Therapeutics received approval from the US Food and Drug Administration for a burn clinical trial using the Cytori Cell...